The anticompetitive regulator, Superintendency of Industry and Commerce, claims Pfizer sold several of its medicines at a price ranging from 4 percent to 651 percent above the agreed-upon amount between July 2016 and December 2016.
The agency claims that Pfizer sold its ophthalmic solution Xalatan for about $33 a unit, when the agency set the price at $4. Additionally, Pfizer’s antidepressant Effexor was sold 348 percent above the official price, according to the regulators.
A Pfizer spokesperson denied the allegations and told STAT the company was complying with the regulator’s investigation.
The move comes as a growing number of countries worldwide are attempting to curb the rising costs of prescription drugs.
Access the full report here.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
